Elective intra-aortic balloon counterpulsation during high-risk percutaneous coronary intervention: a randomized controlled trial.
Divaka Perera,Rodney H. Stables,Martyn Thomas,Jean Booth,Michael Pitt,Daniel J. Blackman,Adam de Belder,Simon Redwood +7 more
TL;DR: The results do not support a strategy of routine IABP placement before PCI in all patients with severe left ventricular dysfunction and extensive coronary disease and suggest that routine intra-aortic balloon counterpulsation before PCI should be dropped.
read more
Abstract: Context Observational studies have previously reported that elective intra-aortic balloon pump (IABP) insertion may improve outcomes following high-risk percutaneous coronary intervention (PCI). To date, this assertion has not been tested in a randomized trial. Objective To determine whether routine intra-aortic balloon counterpulsation before PCI reduces major adverse cardiac and cardiovascular events (MACCE) in patients with severe left ventricular dysfunction and extensive coronary disease. Design, Setting, and Patients The Balloon Pump–Assisted Coronary Intervention Study, a prospective, open, multicenter, randomized controlled trial conducted in 17 tertiary referral cardiac centers in the United Kingdom between December 2005 and January 2009. Patients (n = 301) had severe left ventricular dysfunction (ejection fraction ≤30%) and extensive coronary disease (Jeopardy Score ≥8/12); those with contraindications to or class I indications for IABP therapy were excluded. Intervention Elective insertion of IABP before PCI. Main Outcome Measures Primary end point was MACCE, defined as death, acute myocardial infarction, cerebrovascular event, or further revascularization at hospital discharge (capped at 28 days). Secondary end points included all-cause mortality at 6 months, major procedural complications, bleeding, and access-site complications. Results MACCE at hospital discharge occurred in 15.2% (23/151) of the elective IABP and 16.0% (24/150) of the no planned IABP groups (P = .85; odds ratio [OR], 0.94 [95% confidence interval {CI}, 0.51-1.76]). All-cause mortality at 6 months was 4.6% and 7.4% in the respective groups (P = .32; OR, 0.61 [95% CI, 0.24-1.62]). Fewer major procedural complications occurred with elective IABP insertion compared with no planned IABP use (1.3% vs 10.7%, P Conclusions Elective IABP insertion did not reduce the incidence of MACCE following PCI. These results do not support a strategy of routine IABP placement before PCI in all patients with severe left ventricular dysfunction and extensive coronary disease. Trial Registration isrctn.org Identifier: ISRCTN40553718; clinicaltrials.gov Identifier: NCT00910481
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Feasibility and Safety of High-Risk Percutaneous Coronary Intervention Without Mechanical Circulatory Support.
Nauman Khalid,Toby Rogers,Rebecca Torguson,Cheng Zhang,Corey Shea,Evan Shlofmitz,Yuefeng Chen,Anees Musallam,Jason P. Wermers,Brian C. Case,Hayder Hashim,Itsik Ben-Dor,Nelson L. Bernardo,Lowell F. Satler,Ron Waksman +14 more
24
Incidence of Overall Bleeding in Patients Treated With Intra-Aortic Balloon Pump During Percutaneous Coronary Intervention: 12-Year Milan Experience
Giedrius Davidavicius,Cosmo Godino,Joanne Shannon,Kensuke Takagi,Letizia Bertoldi,Marco Mussardo,Alaide Chieffo,Francesco Arioli,Alfonso Ielasi,Mateo Montorfano,Azeem Latib,Antonio Colombo +11 more
TL;DR: A large cohort of consecutive patients who underwent percutaneous coronary intervention with intra-aortic balloon pump counterpulsation (IABP) support from a tertiary care center over a 12-year period reported a "real-world" experience of in hospital complications and clinical outcome.
23
Intra-Aortic Balloon Pump May Grant No Benefit to Improve the Mortality of Patients With Acute Myocardial Infarction in Short and Long Term: An Updated Meta-Analysis
TL;DR: IABP may be not an optimal therapy in AMI with or without cardiogenic shock until more elaborate classification is used for selecting appropriate patients, and it might promote the risks of hemorrhage and recurrent ischemia.
23
The effectiveness and safety of the Impella ventricular assist device for high-risk percutaneous coronary interventions: A systematic review
Jamal Ait ichou,Natasha Larivée,Natasha Larivée,Mark J. Eisenberg,Karine Suissa,Karine Suissa,Kristian B. Filion +6 more
TL;DR: The objective was to evaluate the effectiveness and safety of the Impella device in high‐risk patients undergoing PCI via a systematic review of the literature.
Outcomes of Impella‐supported high‐risk nonemergent percutaneous coronary intervention in a large single‐center registry
Lorenzo Azzalini,Gurpreet S. Johal,Usman Baber,Jeffrey Bander,Pedro R. Moreno,Lucas Bazi,Vishal Kapur,Nitin Barman,Annapoorna Kini,Samin K. Sharma +9 more
TL;DR: The aim was to evaluate the early and one‐year outcomes of Impella‐supported high‐risk nonemergent percutaneous coronary intervention (PCI).
21
References
Prediction of Creatinine Clearance from Serum Creatinine
Donald W. Cockcroft,M H Gault +1 more
TL;DR: A formula has been developed to predict Creatinine clearance from serum creatinine (Scr) in adult males: Ccr = (140 – age) (wt kg)/72 × Scr (mg/100ml) (15% less i).
15.8K
Universal definition of myocardial infarction
TL;DR: The past history, and likely future of this important topic has been/will remain more “evolution” than “big-bang”, and the current redefinition was flawed at inception owing to a fundamental problem with the troponin assays available at that time.
Universal definition of myocardial infarction.
Kristian Thygesen,Joseph S. Alpert,Harvey D. White,Allan S. Jaffe,Fred S. Apple,Marcello Galvani,Hugo A. Katus,L. Kristin Newby,Jan Ravkilde,Bernard R. Chaitman,Peter Clemmensen,Mikael Dellborg,Hanoch Hod,Pekka Porela,Richard Underwood,Jeroen J. Bax,George A. Beller,Robert O. Bonow,Ernst E. van der Wall,Jean-Pierre Bassand,William Wijns,T. Bruce Ferguson,Philippe Gabriel Steg,Barry F. Uretsky,David O. Williams,Paul W. Armstrong,Elliott M. Antman,Keith A.A. Fox,Christian W. Hamm,E. Magnus Ohman,Maarten L. Simoons,Philip A. Poole-Wilson,Enrique P. Gurfinkel,José-Luis López-Sendón,Prem Pais,Shanti Mendis,Jun-Ren Zhu,Lars Wallentin,Francisco Fernández-Avilés,Kim Fox,Alexander Parkhomenko,Silvia G. Priori,Michal Tendera,Liisa-Maria Voipio-Pulkki,Alec Vahanian,A. John Camm,Raffaele De Caterina,Veronica Dean,Kenneth Dickstein,Gerasimos Filippatos,Christian Funck-Brentano,Irene Hellemans,Steen Dalby Kristensen,Keith McGregor,Udo Sechtem,Sigmund Silber,Petr Widimsky,José Luis Zamorano,João Morais,Sorin J. Brener,Robert A. Harrington,David A. Morrow,Michael J. Lim,Marco A. Martinez-Rios,Steve Steinhubl,Glen N. Levine,W. Brian Gibler,David C. Goff,Marco Tubaro,Darek Dudek,Nawwar Al-Attar +70 more
TL;DR: Information on myocardial infarction attack rates can provide useful data regarding the burden of coronary artery disease within and across populations, especially if standardized data are collected in a manner that demonstrates the distinction between incident and recurrent events.
•Journal Article
The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease.
Georgios Sianos,Marie Angèle Morel,Arie-Pieter Kappetein,Marie Claude Morice,Antonio Colombo,Keith D. Dawkins,van den Brand M,Van Dyck N,Mary E. Russell,Friedrich-Wilhelm Mohr,Patrick W. Serruys +10 more
TL;DR: This poster presents a probabilistic procedure called “Cardialysis BV, Rotterdam, The Netherlands”, which aims to establish a baseline for the use of this procedure in the treatment of chronic kidney disease.
2.2K